Glaxo Pays $175 Million To Settle Antitrust Suit Over Relafen Patent
By Marius Meland ( February 7, 2004, 12:00 AM EST) -- GlaxoSmithKline has agreed to pay $175 million to settle a lawsuit alleging that the company had violated U.S. antitrust law by blocking generic versions of its Relafen arthritis medicine....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.